pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Prostate Cancer, Hot Flush, Advanced Solid Tumors, Advanced cancer of the stomach or the gastroesophageal junction, Ga
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
2215-CL-0603
Phase 2 · small molecule · FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
2215-CL-0603 for FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code 2215-CL-0603
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astellas Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Status
- active
- Trials
- 1